The biotech company Moderna, which is collaborating with the US National Institute of Allergy and Infectious Diseases led by Dr. Anthony Fauci, has reported “positive”…
In a statement Monday, Moderna said that data from the first phase of a clinical trial showed that patients given the vaccine developed an immune response similar to people who acquired the novel coronavirus and recovered. In the Phase 1 trial, eight participants who received two doses of the vaccine – either of 25 micrograms or 100 micrograms – developed neutralizing antibodies “at or above” levels demonstrated in blood samples of recovered COVID-19 patients.
